Patient Compliance
in
Medical Practice and Clinical Trials

Editors

Joyce A. Cramer, B.S.
Project Director, Epilepsy Research
Epilepsy Center
Department of Veterans Affairs Medical Center
West Haven, Connecticut; and
Department of Neurology
Yale University School of Medicine
New Haven, Connecticut

Bert Spilker, Ph.D., M.D.
Director, Project Coordination, Burroughs Wellcome Company
Research Triangle Park, North Carolina
Adjunct Professor of Pharmacology and Clinical Professor of Medicine
University of North Carolina
Clinical Professor of Pharmacy
University of North Carolina School of Pharmacy
Chapel Hill, North Carolina
# Contents

## I. Introduction to the Topic of Patient Compliance

1. Overview of Methods to Measure and Enhance Patient Compliance .......................... 3  
   Joyce A. Cramer

2. Failure to Refill Prescriptions: Incidence, Reasons, and Remedies .......................... 11  
   Richard A. Levy

3. Interaction of Compliance and Patient Safety ..................................................... 19  
   Ronald L. Krall

4. Partial Compliance as a Source of Variance in Pharmacokinetics and Therapeutic Drug Monitoring .......................... 27  
   Julie M. Backes and Jerome J. Schentag

5. Methods of Assessing and Improving Patient Compliance in Clinical Trials .......................... 37  
   Bert Spilker

6. Impact of Risk Communication on Accrual, Regimen, and Follow-up Compliance .......................... 57  
   Louis A. Morris and Ivan Barofsky

## II. Special Patient Populations

7. Compliance with Pediatric Medical Regimens .................................................... 73  
   Michael A. Rapoff and Martha U. Barnard

8. Behavioral Strategies to Increase Compliance in Adolescents .......................... 99  
   Barbara A. Cromer

9. Improving Compliance in the Older Patient: The Role of Comprehensive Functional Assessment .................................................... 107  
   Norma J. Owens, E. Paul Larrat, and Marsha D. Fretwell

## III. Monitoring Techniques for Specific Therapies

10. Monitoring Compliance with Antiepileptic Drug Therapy .................................... 123  
    Joyce A. Cramer and Richard H. Mattson

11. Monitoring Compliance: The Sine Qua Non of Assessing Therapeutics in the Elderly .................................................... 139  
    R. John Dobbs, Sylvia M. Dobbs, and J. Dickins
12. Aerosol Inhaler Monitoring of Asthmatic Medication .......... 149
Sheldon L. Spector and Helen Mawhinney

13. Validity of Standard Compliance Measures in Glaucoma
Compared with an Electronic Eyedrop Monitor ....................... 163
Mae E. Gordon and Michael A. Kass

14. Compliance With Treatment of Hyperlipoproteinemia in
Medical Practice and Clinical Trials ..................................... 175
Wolfgang H.-H. Kruse

15. Clinical Correlates of Antidepressant Compliance ................. 187
Frederick W. Engstrom

16. Oral Contraceptive Compliance and Its Role in the
Effectiveness of the Method ................................................. 195
Linda S. Potter

17. Compliance to Diabetes Regimens: Conceptualization,
Complexity, and Determinants .............................................. 209
Russell E. Glasgow

18. Developing More Clinically Meaningful Definitions of
Medication Compliance ......................................................... 225
Seth A. Eisen

19. Patient Computers to Enhance Compliance with Completing
Questionnaires: A Challenge for the 1990s ......................... 233
Bengt Dahlström and Sven-Åke Eckernäs

IV. Analytical Issues and Approaches

Compliance Data and Clinical Outcomes ................................ 243
Frank L. Hurley

21. Regulatory View: Use of Subgroup Data for Determination
of Efficacy ........................................................................ 251
Russell Katz

22. Biometric Issues in Measuring and Analyzing Partial
Compliance in Clinical Trials ................................................. 265
Joerg Hasford

23. Antihypertensive Drug Trials: Contributions from
Medication Monitors ............................................................. 283
Peter Rudd, Shaheda Ahmed, Valerie Zachary, Carol Barton,
and Delphine Bonduelle

24. Patient Compliance as an Explanatory Variable in Four
Selected Cardiovascular Studies ......................................... 301
John Urquhart
CONTENTS

25. Clinical Trial Prerandomization Compliance (Adherence) Screen ...................................................... 323
   Jeffrey L. Probstfield

26. Patient Selection Bias in Analyses Using Only Compliant Patients ...................................................... 335
   Joseph F. Collins and Walter Dorus

27. Variability of Antiepileptic Medication Concentrations and Compliance .................................................. 349
   Ilo E. Leppik

28. Intent-to-Treat Policy for Analyzing Randomized Trials: Statistical Distortions and Neglected Clinical Challenges .... 359
   Alvan R. Feinstein

V. Perspectives on Health Care and Research

29. Epidemiological and Community Approaches to Patient Compliance .................................................. 373
   Lawrence W. Green, Patricia Dolan Mullen, Rhonda B. Friedman

30. Identifying and Improving Compliance Patterns: A Composite Plan for Health Care Providers ...................... 387
   Joyce A. Cramer

31. Health Care, Research, and Regulatory Impact of Noncompliance .................................................. 393
   Louis Lasagna and Peter Barton Hutt

Subject Index ........................................................................................................................................... 405